Correlation of sex hormone and androgen receptor with diabetes mellitus in elderly men

References

• Haidar A, Yassin A, Saad F, Shabsigh R. Effects of androgen deprivation on glycaemic control and on cardiovascular biochemical risk factors in men with advanced prostate cancer with diabetes. Aging Male 2007;10:189–196.
   PubMed Web of Science ®Google Scholar
• Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24:4448–4456.
   PubMed Web of Science ®Google Scholar
• Fukui M, Soh J, Tanaka M, Kitagawa Y, Hasegawa G, Yoshikawa T, Miki T, Nakamura N. Low serum testosterone concentration in middle-aged men with type 2 diabetes. Endocr J 2007;54:871–877.
   PubMed Web of Science ®Google Scholar
• Saad F, Gooren L. The role of testosterone in the metabolic syndrome: a review. J Steroid Biochem Mol Biol 2009;114:40–43.
   PubMed Web of Science ®Google Scholar
• Cao J, Zou H, Zhu BP, Wang H, Li J, Ding Y, Li XY. Sex hormones and androgen receptor: risk factors of coronary heart disease in elderly men. Chin Med Sci J 2010;25:44–49.
   PubMedGoogle Scholar
• Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2006;295:1288–1299.
   PubMed Web of Science ®Google Scholar
• Haffner SM, Shaten J, Stern MP, Smith GD, Kuller L. Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. Mrfit research group. Multiple risk factor intervention trial. Am J Epidemiol 1996;143:889–897.
   Google Scholar
• Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the massachusetts male aging study. Diabetes Care 2000;23:490–494.
   PubMed Web of Science ®Google Scholar
• Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006;91:1995–2010.
   PubMed Web of Science ®Google Scholar
• Rhoden EL, Ribeiro EP, Teloken C, Souto CA. Diabetes mellitus is associated with subnormal serum levels of free testosterone in men. BJU Int 2005;96:867–870.
   PubMed Web of Science ®Google Scholar
• O’ Donnell AB, Araujo AB, McKinlay JB. The health of normally aging men: the massachusetts male aging study (1987–2004). Exp Gerontol 2004;39:975–984.
   Google Scholar
• Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Valkonen VP, Salonen R, Salonen JT. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004;27:1036–1041.
   PubMed Web of Science ®Google Scholar
• Isidori AM, Caprio M, Strollo F, Moretti C, Frajese G, Isidori A, Fabbri A. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J Clin Endocrinol Metab 1999;84:3673–3680.
   PubMed Web of Science ®Google Scholar
• Marin P, Oden B, Bjorntorp P. Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: effects of androgens. J Clin Endocrinol Metab 1995;80:239–243.
   PubMed Web of Science ®Google Scholar
• Davani B, Khan A, Hult M, Martensson E, Okret S, Efendic S, Jörnvall H, Oppermann UC. Type 1 11beta -hydroxysteroid dehydrogenase mediates glucocorticoid activation and insulin release in pancreatic islets. J Biol Chem 2000;275:34841–34844.
   PubMed Web of Science ®Google Scholar
• Dötsch J, Rascher W. The role of 11beta-hydroxysteroid dehydrogenase activity in the metabolic syndrome: lessons learned from the animal model. Eur J Endocrinol 2002;146:603–605.
   Google Scholar
• Boyanov MA, Boneva Z, Christov VG.Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003;6:1–7.
   PubMedGoogle Scholar
• Shahani S, Braga-Basaria M, Basaria S. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab 2008;93:2042–2049.
   PubMed Web of Science ®Google Scholar
• Pitteloud N Hardin M, Dwyer AA, Valassi E, Yialamas M, Elahi D, Hayes FJ. Increasing insulin resistance is associated with a decrease in leydig cell testosterone secretion in men. J Clin Endocrinol Metab 2005;90:2636–2641.
   PubMed Web of Science ®Google Scholar
• Pitteloud N, Dwyer AA, DeCruz S, Lee H, Boepple PA, Crowley WF Jr, Hayes FJ. Inhibition of luteinizing hormone secretion by testosterone in men requires aromatization for its pituitary but not its hypothalamic effects: evidence from the tandem study of normal and gonadotropin-releasing hormone-deficient men. J Clin Endocrinol Metab 2008;93:784–791.
   PubMed Web of Science ®Google Scholar
• Caprio M, Isidori AM, Carta AR, Moretti C, Dufau ML, Fabbri A. Expression of functional leptin receptors in rodent leydig cells. Endocrinology 1999;140:4939–4947.
   PubMed Web of Science ®Google Scholar
• Hong CY, Park JH, Ahn RS, Im SY, Choi HS, Soh J, Mellon SH, Lee K. Molecular mechanism of suppression of testicular steroidogenesis by proinflammatory cytokine tumor necrosis factor alpha. Mol Cell Biol 2004;24:2593–2604.
   PubMed Web of Science ®Google Scholar
• Pitteloud N, Mootha VK, Dwyer AA, Hardin M, Lee H, Eriksson KF, Tripathy D, Yialamas M, Groop L, Elahi D, Hayes FJ. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 2005;28:1636–1642.
   PubMed Web of Science ®Google Scholar
• Fan W, Yanase T, Nomura M, Okabe T, Goto K, Sato T, Kawano H, Kato S, Nawata H. Androgen receptor null male mice develop late-onset obesity caused by decreased energy expenditure and lipolytic activity but show normal insulin sensitivity with high adiponectin secretion. Diabetes 2005;54(4):1000–1008.
   Google Scholar